Abstract
Hyponatremia frequently occurs in patients with cancer and is mostly due to a syndrome of inappropriate antidiuresis caused by ectopic secretion of antidiuretic hormone (SIADH). Small cell lung cancer presents with SIADH in approximately 11%-15% of cases. Recently, a new class of drugs, vasopressin V2-receptor antagonists (vaptans), emerged as a promising treatment for SIADH, but efficacy and safety data in cancer patients are lacking. We present a case of SIADH, heralding small cell lung cancer and persisting after apparent complete remission of primary tumor following chemotherapy/radiotherapy, in a patient who underwent long-term treatment with tolvaptan without any serious adverse effects.
MeSH terms
-
Antidiuretic Hormone Receptor Antagonists / administration & dosage
-
Antidiuretic Hormone Receptor Antagonists / adverse effects
-
Antidiuretic Hormone Receptor Antagonists / therapeutic use*
-
Benzazepines / administration & dosage
-
Benzazepines / adverse effects
-
Benzazepines / therapeutic use*
-
Chemoradiotherapy
-
Drug Administration Schedule
-
Female
-
Humans
-
Hyponatremia / drug therapy
-
Hyponatremia / etiology*
-
Hyponatremia / prevention & control*
-
Inappropriate ADH Syndrome / complications*
-
Inappropriate ADH Syndrome / drug therapy*
-
Inappropriate ADH Syndrome / etiology
-
Lung Neoplasms / complications*
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / therapy
-
Middle Aged
-
Remission Induction
-
Small Cell Lung Carcinoma / complications*
-
Small Cell Lung Carcinoma / metabolism
-
Small Cell Lung Carcinoma / therapy
-
Tolvaptan
-
Treatment Outcome
Substances
-
Antidiuretic Hormone Receptor Antagonists
-
Benzazepines
-
Tolvaptan